{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T21:16:09Z","timestamp":1765142169310,"version":"build-2065373602"},"reference-count":106,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006058","name":"Saint Baldricks Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["UG1HL069254"],"award-info":[{"award-number":["UG1HL069254"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019225","name":"Pediatric Transplantation and Cellular Therapy Consortium","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019225","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jtct.2024.04.004","type":"journal-article","created":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T01:44:34Z","timestamp":1712454274000},"page":"565-579","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["INSPIRED Symposium Part 5: Expanding the Use of CAR T Cells in Children and Young Adults"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6558-6706","authenticated-orcid":false,"given":"Aimee C.","family":"Talleur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8405-1141","authenticated-orcid":false,"given":"Vanessa A.","family":"Fabrizio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Aplenc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8030-7595","authenticated-orcid":false,"given":"Stephan A.","family":"Grupp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Crystal","family":"Mackall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robbie","family":"Majzner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0670-0599","authenticated-orcid":false,"given":"Rayne","family":"Rouce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5110-004X","authenticated-orcid":false,"given":"Amy","family":"Moskop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4359-3569","authenticated-orcid":false,"given":"Kevin O.","family":"McNerney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2024.04.004_bib0001","first-page":"136","article-title":"Disease burden impacts outcomes in pediatric and young adult B-cell acute lymphoblastic leukemia after commercial tisagenlecleucel: results from the pediatric real world CAR consortium (PRWCC)","author":"Schultz","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2024.04.004_bib0002","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2024.04.004_bib0003","doi-asserted-by":"crossref","first-page":"5737","DOI":"10.1182\/bloodadvances.2021006293","article-title":"Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL","volume":"6","author":"Talleur","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jtct.2024.04.004_bib0004","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood.2022015795","article-title":"CD19\/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR","volume":"140","author":"Shalabi","year":"2022","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.jtct.2024.04.004_bib0005","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.jtct.2024.04.004_bib0006","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jtct.2024.04.004_bib0007","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jtct.2024.04.004_bib0008","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/blood-2017-01-741389","article-title":"Introduction to the review series on T-cell malignancies","volume":"129","author":"Sehn","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2024.04.004_bib0009","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030589","article-title":"Therapeutic advances in relapsed and refractory peripheral T-cell lymphoma","volume":"15","author":"Stuver","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.jtct.2024.04.004_bib0010","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.2022015825","article-title":"Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL","volume":"140","author":"Diorio","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.04.004_bib0011","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3389\/fonc.2019.00126","article-title":"Chimeric antigen receptors for T-cell malignancies","volume":"9","author":"Scherer","year":"2019","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2024.04.004_bib0012","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \"off-the-shelf\" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.jtct.2024.04.004_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2019.101097","article-title":"Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies","volume":"32","author":"Cooper","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"issue":"3","key":"10.1016\/j.jtct.2024.04.004_bib0014","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.jtct.2024.04.004_bib0015","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","article-title":"Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies","volume":"1","author":"Png","year":"2017","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2024.04.004_bib0016","first-page":"321","article-title":"Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial","volume":"140","author":"Lu","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2024.04.004_bib0017","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ymthe.2022.09.003","article-title":"Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies","volume":"31","author":"Watanabe","year":"2023","journal-title":"Mol Ther"},{"issue":"11","key":"10.1016\/j.jtct.2024.04.004_bib0018","doi-asserted-by":"crossref","first-page":"5829","DOI":"10.1073\/pnas.76.11.5829","article-title":"Human lymphocyte antigens: production of a monoclonal antibody that defines functional thymus-derived lymphocyte subsets","volume":"76","author":"Haynes","year":"1979","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.jtct.2024.04.004_bib0019","doi-asserted-by":"crossref","first-page":"517","DOI":"10.4049\/jimmunol.152.2.517","article-title":"Expression and function of CD7 molecule on human natural killer cells","volume":"152","author":"Rabinowich","year":"1994","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.jtct.2024.04.004_bib0020","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","article-title":"A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies","volume":"126","author":"Mamonkin","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2024.04.004_bib0021","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1182\/blood.V77.7.1546.1546","article-title":"Stages of T-cell receptor protein expression in T-cell acute lymphoblastic leukemia","volume":"77","author":"Campana","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.04.004_bib0022","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1146\/annurev.immunol.20.100301.064833","article-title":"Origins and functions of B-1 cells with notes on the role of CD5","volume":"20","author":"Berland","year":"2002","journal-title":"Annu Rev Immunol"},{"issue":"30","key":"10.1016\/j.jtct.2024.04.004_bib0023","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial","volume":"39","author":"Pan","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jtct.2024.04.004_bib0024","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","article-title":"Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study","volume":"32","author":"Hu","year":"2022","journal-title":"Cell Res"},{"key":"10.1016\/j.jtct.2024.04.004_bib0025","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1182\/blood-2022-165819","article-title":"Efficacy and safety of donor-derived CD7 CAR T cells for r\/r T-cell acute lymphoblastic leukemia\/lymphoma: interim analysis from a phase 2 trial","volume":"140","author":"Tan","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2024.04.004_bib0026","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13045-023-01427-3","article-title":"Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia","volume":"16","author":"Tan","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2024.04.004_bib0027","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jtct.2022.11.013","article-title":"Donor CD7 chimeric antigen receptor T cell bridging to allogeneic hematopoietic stem cell transplantation for T cell hematologic malignancy","volume":"29","author":"Li","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"13","key":"10.1016\/j.jtct.2024.04.004_bib0028","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1158\/1078-0432.CCR-21-4097","article-title":"Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia\/lymphoma","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2024.04.004_bib0029","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1182\/blood-2021-154142","article-title":"Early signals of anti-tumor efficacy and safety with autologous CD5.CAR T-cells in patients with refractory\/relapsed T-cell lymphoma","volume":"138","author":"Rouce","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.04.004_bib0030","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood-2019-129559","article-title":"Safety and anti-tumor activity of CD5 CAR T-cells in patients with relapsed\/refractory T-cell malignancies","volume":"134","author":"Hill","year":"2019","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.jtct.2024.04.004_bib0031","first-page":"1","article-title":"Enhanced anti-tumor activity of CD5 CAR T cells manufactured with tyrosine kinase inhibitors in patients with relapsed\/refractory T-ALL","volume":"41","author":"Hill","year":"2023","journal-title":"JCO"},{"issue":"4","key":"10.1016\/j.jtct.2024.04.004_bib0032","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2024.04.004_bib0033","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/MOP.0000000000000855","article-title":"Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy","volume":"32","author":"Elgarten","year":"2020","journal-title":"Curr Opin Pediatr"},{"issue":"2","key":"10.1016\/j.jtct.2024.04.004_bib0034","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.jtct.2024.04.004_bib0035","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"issue":"16","key":"10.1016\/j.jtct.2024.04.004_bib0036","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2024.04.004_bib0037","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2024.04.004_bib0038","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41375-021-01350-x","article-title":"Catch me if you can: how AML and its niche escape immunotherapy","volume":"36","author":"Tettamanti","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2024.04.004_bib0039","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fonc.2020.00262","article-title":"A bump in the road: how the hostile AML microenvironment affects CAR T cell therapy","volume":"10","author":"Epperly","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2024.04.004_bib0040","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.hoc.2023.06.004","article-title":"Chimeric antigen receptor T cells in acute myeloid leukemia","volume":"37","author":"Cummins","year":"2023","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jtct.2024.04.004_bib0041","first-page":"4584","article-title":"CD33 CAR T-cells (CD33CART) for children and young adults with relapsed\/refractory AML: dose-escalation results from a phase I\/II multicenter trial","volume":"140","author":"Shah","year":"2023","journal-title":"ASH Annual Meeting"},{"key":"10.1016\/j.jtct.2024.04.004_bib0042","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1182\/blood-2022-170201","article-title":"Safety and anti-leukemic activity of CD123-CAR T cells in pediatric patients with AML: preliminary results from a phase 1 trial","volume":"140","author":"Naik","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2024.04.004_bib0043","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","article-title":"Pharmacologic control of CAR-T cell function using dasatinib","volume":"3","author":"Weber","year":"2019","journal-title":"Blood Adv"},{"issue":"suppl 16","key":"10.1016\/j.jtct.2024.04.004_bib0044","doi-asserted-by":"crossref","first-page":"TPS7078","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS7078","article-title":"Pediatric and young adult leukemia adoptive therapy (PLAT)-08: a phase 1 study of SC-DARIC33 in pediatric and young adults with relapsed or refractory CD33+ AML","volume":"40","author":"Cooper","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2024.04.004_bib0045","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-182104","article-title":"Cytokine release syndrome results in reduced AML killing by CD123 CAR T cells","volume":"142","author":"Bhagwat","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2024.04.004_bib0046","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1002\/ijc.32028","article-title":"Targeting the arginine metabolic brake enhances immunotherapy for leukaemia","volume":"145","author":"Mussai","year":"2019","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.jtct.2024.04.004_bib0047","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.20020121","article-title":"Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase","volume":"196","author":"Frumento","year":"2002","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.jtct.2024.04.004_bib0048","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/bjh.12774","article-title":"Contribution of CD39 to the immunosuppressive microenvironment of acute myeloid leukaemia at diagnosis","volume":"165","author":"Dulphy","year":"2014","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.jtct.2024.04.004_bib0049","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.3324\/haematol.2012.066399","article-title":"Remission maintenance in acute myeloid leukemia: impact of functional histamine H2 receptors expressed by leukemic cells","volume":"97","author":"Aurelius","year":"2012","journal-title":"Haematologica"},{"issue":"22","key":"10.1016\/j.jtct.2024.04.004_bib0050","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1158\/1078-0432.CCR-17-3016","article-title":"Novel approaches to acute myeloid leukemia immunotherapy","volume":"24","author":"Beyar-Katz","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.jtct.2024.04.004_bib0051","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.jtct.2024.04.004_bib0052","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s43018-021-00319-0","article-title":"The current landscape of immunotherapy for pediatric brain tumors","volume":"3","author":"Hwang","year":"2022","journal-title":"Nat Cancer"},{"issue":"8","key":"10.1016\/j.jtct.2024.04.004_bib0053","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMc1704610","article-title":"Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma","volume":"377","author":"Abramson","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jtct.2024.04.004_bib0054","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1038\/s41375-019-0437-5","article-title":"Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL","volume":"33","author":"He","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2024.04.004_bib0055","article-title":"CAR T cell therapy in primary brain tumors: current investigations and the future","volume":"13","author":"Lin","year":"2022","journal-title":"Front Immunol"},{"issue":"21","key":"10.1016\/j.jtct.2024.04.004_bib0056","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215445","article-title":"CAR T cell therapy's potential for pediatric brain tumors","volume":"13","author":"Thomas","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.jtct.2024.04.004_bib0057","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/neuonc\/nou330","article-title":"Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma","volume":"17","author":"Truffaux","year":"2015","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jtct.2024.04.004_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100870","article-title":"Locoregional CAR T cells for children with CNS tumors: clinical procedure and catheter safety","volume":"36","author":"Vitanza","year":"2023","journal-title":"Neoplasia"},{"issue":"4","key":"10.1016\/j.jtct.2024.04.004_bib0059","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","article-title":"Tumor inflammation-associated neurotoxicity","volume":"29","author":"Mahdi","year":"2023","journal-title":"Nat Med"},{"issue":"7903","key":"10.1016\/j.jtct.2024.04.004_bib0060","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"issue":"suppl 12","key":"10.1016\/j.jtct.2024.04.004_bib0061","doi-asserted-by":"crossref","first-page":"CT001","DOI":"10.1158\/1538-7445.AM2022-CT001","article-title":"Abstract CT001: major tumor regressions in H3K27M-mutated diffuse midline glioma (DMG) following sequential intravenous (IV) and intracerebroventricular (ICV) delivery of GD2-CAR T cells","volume":"82","author":"Majzner","year":"2022","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.jtct.2024.04.004_bib0062","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial","volume":"3","author":"Ahmed","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2024.04.004_bib0063","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","article-title":"Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety","volume":"13","author":"Vitanza","year":"2023","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.jtct.2024.04.004_bib0064","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1038\/s41591-021-01404-8","article-title":"Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis","volume":"27","author":"Vitanza","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2024.04.004_bib0065","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13Ralpha2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.jtct.2024.04.004_bib0066","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","article-title":"Navigating CAR-T cells through the solid-tumour microenvironment","volume":"20","author":"Hou","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"10.1016\/j.jtct.2024.04.004_bib0067","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","article-title":"CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma","volume":"25","author":"Heczey","year":"2017","journal-title":"Mol Ther"},{"issue":"23","key":"10.1016\/j.jtct.2024.04.004_bib0068","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2024.04.004_bib0069","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.1882","article-title":"Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma","volume":"14","author":"Pule","year":"2008","journal-title":"Nat Med"},{"issue":"571","key":"10.1016\/j.jtct.2024.04.004_bib0070","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd6169","article-title":"Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma","volume":"12","author":"Straathof","year":"2020","journal-title":"Sci Transl Med"},{"issue":"14","key":"10.1016\/j.jtct.2024.04.004_bib0071","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for relapsed or refractory high-risk neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N Engl J Med"},{"issue":"7952","key":"10.1016\/j.jtct.2024.04.004_bib0072","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","article-title":"Co-opting signalling molecules enables logic-gated control of CAR T cells","volume":"615","author":"Tousley","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jtct.2024.04.004_bib0073","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"2","key":"10.1016\/j.jtct.2024.04.004_bib0074","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","article-title":"Engineering T cells with customized therapeutic response programs using synthetic notch receptors","volume":"167","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jtct.2024.04.004_bib0075","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/j.ymthe.2023.04.008","article-title":"Optimized CAR-T therapy based on spatiotemporal changes and chemotactic mechanisms of MDSCs induced by hypofractionated radiotherapy","volume":"31","author":"Zhang","year":"2023","journal-title":"Molecular Therapy"},{"issue":"32","key":"10.1016\/j.jtct.2024.04.004_bib0076","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","article-title":"Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens","volume":"26","author":"Dudley","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2024.04.004_bib0077","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","article-title":"Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy","volume":"12","author":"Herrera","year":"2022","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.jtct.2024.04.004_bib0078","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2158013","article-title":"Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors","volume":"12","author":"Laurent","year":"2023","journal-title":"Oncoimmunology"},{"issue":"5","key":"10.1016\/j.jtct.2024.04.004_bib0079","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001743","article-title":"Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy","volume":"9","author":"Nissani","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.jtct.2024.04.004_bib0080","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.ymthe.2021.02.024","article-title":"Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity","volume":"29","author":"Murad","year":"2021","journal-title":"Mol Ther"},{"issue":"48","key":"10.1016\/j.jtct.2024.04.004_bib0081","doi-asserted-by":"crossref","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","article-title":"Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells","volume":"113","author":"Hurton","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.jtct.2024.04.004_bib0082","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat Biotechnol"},{"issue":"6625","key":"10.1016\/j.jtct.2024.04.004_bib0083","first-page":"eaba1624","article-title":"Synthetic cytokine circuits that drive T cells into immune-excluded tumors","volume":"378","author":"Allen","year":"2022","journal-title":"Science (1979)"},{"issue":"4","key":"10.1016\/j.jtct.2024.04.004_bib0084","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/mt.2010.313","article-title":"Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment","volume":"19","author":"Zhang","year":"2011","journal-title":"Mol Ther"},{"issue":"7","key":"10.1016\/j.jtct.2024.04.004_bib0085","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.celrep.2018.04.051","article-title":"Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system","volume":"23","author":"Avanzi","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.jtct.2024.04.004_bib0086","first-page":"xi12","article-title":"35O - Phase I clinical trial of PD-1 knockout anti-MUC1 CAR-T cells in the treatment of patients with non-small cell lung cancer","volume":"30","author":"Lin","year":"2019","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2024.04.004_bib0087","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","article-title":"Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors","volume":"18","author":"Wang","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"10.1016\/j.jtct.2024.04.004_bib0088","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGFbeta-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.jtct.2024.04.004_bib0089","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1158\/2159-8290.CD-17-1417","article-title":"Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 (c259)T cells in synovial sarcoma","volume":"8","author":"D'Angelo","year":"2018","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.jtct.2024.04.004_bib0090","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.mt.6300104","article-title":"Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma","volume":"15","author":"Park","year":"2007","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtct.2024.04.004_bib0091","article-title":"ENCIT-01: a phase 1 study of autologous T-cells lentivirally transduced to express CD171-specific chimeric antigen receptors for recurrent\/refractory high-risk neuroblastoma","author":"Pinto","year":"2018","journal-title":"Adv Neuroblastoma Res"},{"issue":"15","key":"10.1016\/j.jtct.2024.04.004_bib0092","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2024.04.004_bib0093","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1038\/s41467-020-17175-8","article-title":"Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma","volume":"11","author":"Hegde","year":"2020","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.jtct.2024.04.004_bib0094","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jcyt.2020.04.088","article-title":"Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: a phase I clinical trial","volume":"22","author":"Liu","year":"2020","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.jtct.2024.04.004_bib0095","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2024.04.004_bib0096","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2017.35.15_suppl.10508","article-title":"Expansion of HER2-CAR T cells after lymphodepletion and clinical responses in patients with advanced sarcoma","volume":"35","author":"Hegde","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7786","key":"10.1016\/j.jtct.2024.04.004_bib0097","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"c-Jun overexpression in CAR T cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jtct.2024.04.004_bib0098","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1089\/hum.2017.234","article-title":"Nucleofection with plasmid DNA for CRISPR\/Cas9-mediated inactivation of programmed cell death protein 1 in CD133-specific CAR T cells","volume":"30","author":"Hu","year":"2019","journal-title":"Hum Gene Ther"},{"issue":"7","key":"10.1016\/j.jtct.2024.04.004_bib0099","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative TGF-beta receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol Ther"},{"issue":"23","key":"10.1016\/j.jtct.2024.04.004_bib0100","doi-asserted-by":"crossref","first-page":"34341","DOI":"10.18632\/oncotarget.9114","article-title":"Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model","volume":"7","author":"Suarez","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.jtct.2024.04.004_bib0101","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1158\/2159-8290.CD-17-0538","article-title":"Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells","volume":"7","author":"Shum","year":"2017","journal-title":"Cancer Discov"},{"issue":"22","key":"10.1016\/j.jtct.2024.04.004_bib0102","doi-asserted-by":"crossref","first-page":"6982","DOI":"10.1158\/1078-0432.CCR-17-0867","article-title":"Enhanced cancer immunotherapy by chimeric antigen receptor-modified T cells engineered to secrete checkpoint inhibitors","volume":"23","author":"Li","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"215","key":"10.1016\/j.jtct.2024.04.004_bib0103","doi-asserted-by":"crossref","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med"},{"issue":"15","key":"10.1016\/j.jtct.2024.04.004_bib0104","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1158\/1078-0432.CCR-21-1356","article-title":"Immunotherapy of neuroblastoma: facts and hopes","volume":"28","author":"Anderson","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"7949","key":"10.1016\/j.jtct.2024.04.004_bib0105","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jtct.2024.04.004_bib0106","doi-asserted-by":"crossref","first-page":"7200","DOI":"10.1038\/s41467-021-27312-6","article-title":"Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients","volume":"12","author":"Maschan","year":"2021","journal-title":"Nat Commun"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724003439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724003439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:01:25Z","timestamp":1762639285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724003439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":106,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2666636724003439"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.04.004","relation":{},"ISSN":["2666-6367"],"issn-type":[{"type":"print","value":"2666-6367"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"INSPIRED Symposium Part 5: Expanding the Use of CAR T Cells in Children and Young Adults","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}